.png "Insmed (NASDAQ: INSM)")
Today, the Chief People Strategy Officer of Insmed, Orlov Nicole Schaeffer, exercised options of Insmed (NASDAQ: INSM) for $1.05M.
Following Orlov Nicole Schaeffer’s last INSM Sell transaction on November 09, 2016, the stock climbed by 14.3%.
See today’s analyst top recommended stocks >>
Currently, Insmed has an average volume of 538.2K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $42.25, reflecting a -33.6% downside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.
